Mouse Study Shows Tirzepatide Slows Growth of Obesity-Related Breast Cancer
A groundbreaking mouse study presented at ENDO 2025 shows that tirzepatide, an anti-obesity medication, can slow the growth of breast cancer linked to obesity. These findings may pave the way for new cancer treatments targeting obesity-related pathways.
A recent study presented at ENDO 2025, the annual meeting of the Endocrine Society in San Francisco, has revealed promising findings on the effects of tirzepatide, an anti-obesity medication, on breast cancer in a mouse model. Known commercially as Mounjaro for diabetes and Zepbound for obesity, tirzepatide was found to significantly reduce breast tumor growth in mice that were made obese through a high-fat diet.
In this study, 16 nine-week-old C57BL/6 mice were fed a diet consisting of 40% fat to induce obesity. At 32 weeks, the obese mice received injections of tirzepatide or a placebo every other day for a period of 16 weeks, with tumor sizes measured twice weekly. The mice treated with tirzepatide experienced a weight and fat reduction of approximately 20%, mainly due to loss of adipose tissue, with a significant decrease in fat depot weights compared to untreated controls.
The key finding was that tumor volume was markedly smaller in the mice receiving tirzepatide. At the study’s conclusion, tumor size was closely linked to body weight, total adipose tissue, and liver fat content. These results suggest that tirzepatide, beyond its role in weight management, might have a beneficial impact on breast cancer outcomes, especially in cases linked to obesity.
"While these findings are preliminary, they indicate that anti-obesity drugs like tirzepatide may help reduce breast cancer risk or improve treatment results," explained study author Amanda Kucinskas, a Ph.D. candidate at the University of Michigan. The ongoing research aims to distinguish the effects of weight loss itself from those directly related to the tumor, collaborating with experts at the University of North Carolina.
Obesity is a known risk factor for poorer breast cancer prognosis, with weight loss often leading to better outcomes. However, traditional weight management methods face many challenges. The study highlights tirzepatide’s dual potential for weight reduction and cancer treatment, opening new avenues for research in obesity-related cancer therapies.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Dark Spots Under Fingernails Could Indicate Serious Skin Cancer
A dark spot under your fingernail could be a sign of a rare and aggressive form of skin cancer called subungual melanoma. Early detection is key to effective treatment.
New Insights into Treatment Resistance in ER+ Breast Cancer: The Role of the JNK Pathway
A new study uncovers how inactivation of the JNK pathway enables ER+ breast cancer cells to evade treatment, offering potential for targeted therapies and improved patient outcomes.
New Insights into the Genetic Mutations Behind Weaver Syndrome
Researchers have revealed how mutations in the EZH2 gene actively disrupt chromatin regulation, driving Weaver syndrome and related overgrowth conditions. This discovery advances understanding of genetic and epigenetic factors in developmental disorders.
Innovative Synthetic Lipoprotein Strategy Targets Cancer Metabolism to Induce Cell Death
A groundbreaking study reveals how a synthetic lipoprotein can induce ferroptosis in resistant cancer cells by disrupting their metabolic defenses, offering new hope for targeted cancer therapy.